Merck FY 2023: revenue $60.1B, up 1%; diluted EPS $0.14

Key figures from this report

These are the numbers Merck reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Revenue$60.1B+1% from $59.3B in FY 202210-K income statement, on EDGAR
2. Net income$365.0M−97% from $14.5B in FY 202210-K income statement, on EDGAR
3. Diluted EPS$0.14−98% from $5.71 in FY 202210-K income statement, on EDGAR
4. Cash and cash equivalents$6.8B−46% from $12.7B in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
5. Cash from operations$13.0B−32% from $19.1B in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables